DNA Interstrand Cross-Linking Agents and their Chemotherapeutic Potential

被引：46

作者：

Brulikova, L. ^{[1
]}

Hlavac, J. ^{[1
]}

Hradil, P. ^{[1
]}

机构：

[1] Palacky Univ, Fac Sci, Inst Mol & Translat Med, Dept Organ Chem, Olomouc 77146, Czech Republic

来源：

CURRENT MEDICINAL CHEMISTRY | 2012年 / 19卷 / 03期

关键词：

Chemotherapy; cytotoxicity; DNA; interstrand cross-link; ICL; repair; resistance; NUCLEOTIDE EXCISION-REPAIR; FANCONI-ANEMIA PATHWAY; GROUP DOMAIN PROTEINS; MINOR-GROOVE; ANTITUMOR-ACTIVITY; CANCER CELLS; IN-VITRO; ATAXIA-TELANGIECTASIA; REDUCTIVE ACTIVATION; SELECTIVE INHIBITOR;

D O I：

10.2174/092986712803414295

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

DNA interstrand cross-linking (ICL) agents are an important group of cytotoxic drugs with the capability of binding covalently between two strands of DNA, thereby preventing vital processes such as replication or transcription in dividing cells. In anticancer therapy however, their potential is limited due to the resistance by various mechanisms. In order to develop highly effective antitumor drugs it is necessary to study both effective ICL formations and their subsequent repair mechanisms. This review presents an overview of development over the past decade and the use of both well-known and new DNA interstrand cross-linking agents. Their potential in applications especially as anticancer chemotherapeutics in the framework of current knowledge of repair mechanisms and development of combined chemotherapy is discussed.

引用

页码：364 / 385

页数：22

共 136 条

[1] Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer
Aghajanian, C
Dizon, DS
Sabbatini, P
Raizer, JJ
Dupont, J
Spriggs, DR
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) : 5943 - 5949
[2] Functionalised cyclopentadienyl titanium compounds as potential anticancer drugs
Allen, Olivia R.
Gott, Andrew L.
Hartley, John A.
Hartley, Janet M.
Knox, Richard J.
McGowan, Patrick C.
[J]. DALTON TRANSACTIONS, 2007, (43) : 5082 - 5090
[3] Preparation and characterization of platinum(II) and (M complexes of 1,3-diaminepropane and 1,4-diaminebutane:: Circumvention of cisplatin resistance and DNA interstrand cross-link formation in CH1cisR ovarian tumor cells
Alvarez-Valdés, A
Pérez, JM
López-Solera, I
Lannegrand, R
Continente, JM
Amo-Ochoa, P
Camazón, MJ
Solans, X
Font-Bardía, M
Navarro-Ranninger, C
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (09) : 1835 - 1844
[4] Sequence-specific DNA interstrand cross-linking by imidazole-pyrrole CPI conjugate
Bando, T
Iida, H
Saito, I
Sugiyama, H
[J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2001, 123 (21) : 5158 - 5159
[5] Highly efficient sequence-specific DNA interstrand cross-linking by pyrrole/imidazole CPI conjugates
Bando, T
Narita, A
Saito, I
Sugiyama, H
[J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2003, 125 (12) : 3471 - 3485
[6] Chk1 and Chk2 kinases in checkpoint control and cancer
Bartek, J
Lukas, J
[J]. CANCER CELL, 2003, 3 (05) : 421 - 429
[7] C-1027, A Radiomimetic Enediyne Anticancer Drug, Preferentially Targets Hypoxic Cells
Beerman, Terry A.
Gawron, Loretta S.
Shin, Seulkih
Shen, Ben
McHught, Mary M.
[J]. CANCER RESEARCH, 2009, 69 (02) : 593 - 598
[8] Checkpoint Signaling from a Single DNA Interstrand Crosslink
Ben-Yehoyada, Merav
Wang, Lily C.
Kozekov, Ivan D.
Rizzo, Carmelo J.
Gottesman, Max E.
Gautier, Jean
[J]. MOLECULAR CELL, 2009, 35 (05) : 704 - 715
[9] Phase I/II trial assessing bortezomlb and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma
Berenson, JR
Yang, HH
Sadler, K
Jarutirasarn, SG
Vescio, RA
Mapes, R
Purner, M
Lee, SP
Wilson, J
Morrison, B
Adams, J
Schenkein, D
Swift, R
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (06) : 937 - 944
[10] Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents
Boone, Julien J. M.
Bhosle, Jaishree
Tilby, Mike J.
Hartley, John A.
Hochhauser, Daniel
[J]. MOLECULAR CANCER THERAPEUTICS, 2009, 8 (11) : 3015 - 3023

← 1 2 3 4 5 6 7 8 9 10 →